Session Title: New drug treatment and technology
Session Date/Time: Friday 27/09/2013 | 14:30-16:00
Paper Time: 15:50
Venue: Hall 3 (Level 0)
First Author: C.Eandi ITALY
Co Author(s): C. Alovisi F. Tridico F. Grignolo
To study a follow-up and monitoring visit schedule for patients treated with dexamethasone intravitreal implant (DEX implant; Ozurdex, Allergan, Inc., Irvine, CA) for macular edema secondary to retinal vein occlusion (BRVO or CRVO).
Prospective case series
We included 22 (15 M; 7 F) patients with a history of macular edema secondary to branch (n: 15) or central retinal vein occlusion (n: 7). At baseline patients received DEX implant 0.7 mg. Best-corrected visual acuity (BCVA), Spectral Domain Ocular Coherence Tomography (SDOCT) and intraocular pressure (IOP) were tested at each follow-up visit, and in particular at day one, week one and monthly. Mean follow-up was 6.95 months.
At baseline BCVA was 20/100 and remained stable throughout the follow-up period. Central retinal thickness (CRT) was 451,5 (±257,3) microns at baseline, 313,2 (± 114,5) microns at month one and 321 (±76,8) microns at month four showing a recurrence of intraretinal fluid. IOP increased from 15,3 (± 1.15) mmHg(G) at baseline to 18 mmHg(G) at month 2, and 22 (±8,7) mmHg(G) at month three. The time-window for retreatment was 4 months.
In our study we found that the IOP increased at month 2, while the recurrences were evident starting from month 4. Therefore, the follow-up visit should be scheduled at month 2 and 4 in order to monitor the IOP changes and recurrences.